Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;19(8):870-4.
doi: 10.1038/ejhg.2011.37. Epub 2011 Mar 16.

Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation

Marjolijn C J Jongmans  1 , Ineke van der Burgt, Peter M Hoogerbrugge, Kees Noordam, Helger G Yntema, Willy M Nillesen, Roland P Kuiper, Marjolijn J L Ligtenberg, Ad Geurts van Kessel, J Han J M van Krieken, Lambertus A L M Kiemeney, Nicoline Hoogerbrugge
Affiliations

Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation

Marjolijn C J Jongmans et al. Eur J Hum Genet. 2011 Aug.

Abstract

Noonan syndrome (NS) is characterized by short stature, facial dysmorphisms and congenital heart defects. PTPN11 mutations are the most common cause of NS. Patients with NS have a predisposition for leukemia and certain solid tumors. Data on the incidence of malignancies in NS are lacking. Our objective was to estimate the cancer risk and spectrum in patients with NS carrying a PTPN11 mutation. In addition, we have investigated whether specific PTPN11 mutations result in an increased malignancy risk. We have performed a cohort study among 297 Dutch NS patients with a PTPN11 mutation (mean age 18 years). The cancer histories were collected from the referral forms for DNA diagnostics, and by consulting the Dutch national registry of pathology and the Netherlands Cancer Registry. The reported frequencies of cancer among NS patients were compared with the expected frequencies using population-based incidence rates. In total, 12 patients with NS developed a malignancy, providing a cumulative risk for developing cancer of 23% (95% confidence interval (CI), 8-38%) up to age 55 years, which represents a 3.5-fold (95% CI, 2.0-5.9) increased risk compared with that in the general population. Hematological malignancies occurred most frequently. Two malignancies, not previously observed in NS, were found: a malignant mastocytosis and malignant epithelioid angiosarcoma. No correlation was found between specific PTPN11 mutations and cancer occurrence. In conclusion, this study provides first evidence of an increased risk of cancer in patients with NS and a PTPN11 mutation, compared with that in the general population. Our data do not warrant specific cancer surveillance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age-specific cumulative risk of cancer in patients with Noonan syndrome and a mutation in PTPN11. We found a cumulative risk of 23% (95% CI, 7.6–38.4%) up to age of 55 years, which represents a 3.5-fold increased risk (95% CI, 2.0–5.9) compared with the general population.
See this image and copyright information in PMC

References

    1. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1:2–26. - PMC - PubMed
    1. Choong K, Freedman MH, Chitayat D, Kelly EN, Taylor G, Zipursky A. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol. 1999;21:523–527. - PubMed
    1. Lauchle JO, Braun BS, Loh ML, Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer. 2006;46:579–585. - PubMed
    1. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Curr Opin Hematol. 2004;11:44–50. - PubMed
    1. Chantrain CF, Jijon P, De RT, et al. Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation. Pediatr Blood Cancer. 2007;48:101–104. - PubMed

Publication types

MeSH terms

Substances